Triple therapy with clarithromycin, amoxicillin and omeprazole for Helicobacter pylori eradication in children and adolescents

Arquivos de Gastroenterologia

Elisabete Kawakami²  Silvio Kazuo Ogata²  Áurea C. M. Portorreal²  Ana Maria Magni¹  Mário Luís E. Pardo²  Francy R. S. PatrÍcio¹ 

[1] ,UNIFESP EPM Division of Pediatric Gastroenterology

关键词: Clarithromycin;    Amoxicillin;    Omeprazole;    Helicobacter infections;    Child;    Adolescence;    Claritromicina;    Amoxicilina;    Omeprazol;    Infecções por helicobacter;    Criança;    Adolescência;   

DOI  :  10.1590/S0004-28032001000300011

来源: SciELO

【 摘 要 】

Background — Helicobacter pylori infection presents high prevalence in developing countries, but there are few pediatric assays evaluating antimicrobial treatment. Objective - The aim of this study was to investigate Helicobacter pylori eradication rate using a short regimen (7 and 10 days) of triple therapy with clarithromycin, amoxicillin and omeprazole. Patients and methods - Twenty-five Hp positive patients who presented severe epigastralgia, were submitted to antimicrobial treatment with amoxicillin (50 mg/kg/day - maximum dose 1g bid), clarithromycin (30 mg/kg/day - maximum dose 500 mg bid) and omeprazole (0.6 mg/kg/day - maximum dose 20 mg bid) during 7 or 10 days. After 2 months, clinical symptoms were evaluated and gastric biopsies were taken to test Hp eradication. Results - Overall eradication rate was achieved in 16/25 patients (64% - IC(95%) = 45-83%), in 11/15 (73% - IC(95%) = 51-95%) patients who used 10 days therapy course and in 5/10 (50% - IC(95%) = 19-81%) who used 7 days therapy course. Eradication drugs were well accepted and adverse effects were reported in two patients (8%). Conclusions - This triple therapy regimen had moderate efficacy (64%). The data suggests that 10 days therapy course achieves better eradication rate (73%) than 7 days course (50%) to treat Hp infection in our population.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License